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 Murine genetic models of human disor-
ders have contributed numerous insights 
into disease pathogenesis. Unlike the 
genetic variation in humans, there is 
 relatively little genetic diversity among 
the commonly used strains of laboratory 
mice. This is primarily because most 
 laboratory strains originated from a small 
number of ancestral animals. 1,2 Purposeful 
inbreeding of mice further limits the 
genetic diversity. Aft er 20  generations of 
inbreeding, on average at least 98.6 % of 
loci become homozygous. 1 Many strains 
have been bred for more than 100 
 generations and thus are completely 
homozygous at all loci. Such intra-strain 
isogenicity is particularly useful in studies 
that seek to eliminate genetic variation as 
one of the experimental variables. On the 
other hand, the inter-strain genetic and 
phenotypic differences have been the 
backbone of traditional quantitative trait 
locus (QTL) linkage mapping in mouse 
genetics, where the segregation of known 
genetic markers is tested against the seg-
regation of quantitative phenotypes in F 2 
or backcross off spring populations. While 
powerful, these classic QTL analyses 
depend on many years of expensive 
 scientifi c labor to breed, genotype, and 
phenotype the appropriate intercrosses 
for analyses, as each F 2 mouse is geneti-
cally unique. In addition, because of the 
limited amount of recombination in these 
populations, the identifi ed QTL intervals 
are usually very large, on the order of 
40 – 50  Mb, making it diffi  cult to pinpoint 
the causal genes. 
 Th e more recent haplotype-based meth-
ods demonstrate great promise for tackling 
the issues of cost, time, and resolution. 3 
Th ese methods take full advantage of the 
fact that inbred strains are homozygous 
(that is, they have no intra-strain individ-
ual genetic variation), thus their haplotype 
structure is fi xed. Th is makes them quasi-
immortal, presenting an opportunity to 
comprehensively genotype each strain 
once, while phenotyping can be repeated 
indefi nitely. Additionally, replication of 
phenotype measurements in genetically 
identical organisms reduces the eff ect of 
environmental factors. Since inbred labo-
ratory mice share common ancestors, his-
toric recombinations have scrambled the 
inter-strain genetic variation, resulting in 
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 Genome-wide haplotype association mapping (HAM) in inbred mouse 
strains emerged as an efficient method for identifying novel 
quantitative trait loci for disease-related phenotypes. In this issue of 
Kidney International, Tsaih  et al. present the results of the first HAM for 
age-related kidney damage in mice and examine the detected loci in 
the context of the human genome-wide association study for diabetic 
nephropathy. 
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genomes that are mosaics of the ancestral 
haplotypes ( Figure 1 ). Th e method of hap-
lotype association mapping (HAM) treats 
inbred mouse lines as if they were indi-
viduals from a larger outbred population. 
Th e HAM approach tests each of the hap-
lotype blocks across the genome for asso-
ciation with a phenotype of interest. 
Haplotype blocks are potentially  powerful 
in association studies because each block 
can be distinguished by genotyping a rela-
tively small fraction of polymorphisms. As 
is evident from  Figure 1 , the size of haplo-
type blocks decreases with the number of 
carefully selected strains, increasing the 
fi nal resolution of the method. 4 
 Th e most important progress in this type 
of approach can be attributed to the devel-
opment of high-throughput sequencing 
technologies that enabled accurate discov-
ery of single-nucleotide polymorphisms 
(SNPs) across the mouse genome. Dense 
genotypic information for an increasing 
number of inbred strains is becoming pub-
licly available. 5,6 For example, the Mouse 
Phenome Database ( http://www.jax.org/
phenome ) currently contains the genotype 
data for 16 strains assayed at over 8 million 
SNPs and 72 strains assayed at more than 
500,000 locations, with a mixture of actual 
and imputed data being available for 74 
strains at 7.8 million locations. Moreover, 
97 diff erent phenotypes have been mus-
tered across inbred strains and are publicly 
available for download. In addition, the 
ongoing Collaborative Cross project aims 
at establishing a large panel of recombinant 
inbred mouse strains derived from a set of 
eight well-characterized inbred founder 
strains. 7 Th is project is designed specifi -
cally to provide adequate power and reso-
lution for QTL detection in complex trait 
analyses. Public availability of these data 
holds a great potential to accelerate gene 
discovery for many disease-related quan-
titative traits. 
 Tsaih and colleagues 8 (this issue) 
applied the HAM approach to identify 
potential QTLs for age-related proteinu-
ria in mice. It is well established that the 
aging process elicits a number of struc-
tural and functional changes in kidneys. 9 
In humans, the most characteristic is the 
reduction of functioning kidney mass 
see original article on page 201
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 MYO16 and  IRS2 genes (chromosome 
13q), and one in the intronic region of 
 NEGR1 (chromosome 1p). 
 This study exemplifies the utility of 
 in silico analysis of mouse genetic data to 
accelerate the discovery of variants that 
are potentially involved in human disease. 
Th e availability of dense genotype data 
for many inbred strains allows testing of 
almost any phenotype that can be poten-
tially associated with disease pathogene-
sis. Th e homozygous nature of the inbred 
strains eliminates most of the genetic 
complexity of epigenetic, recessive, or 
dominant eff ects frequently observed in 
heterozygotes. Moreover, the online 
availability of comprehensive phenotype 
and genotype data allows researchers 
to reduce genome-wide QTL searches 
to minutes. 
 Nevertheless, several limitations of this 
approach need to be noted. First, the gen-
otyping data for many of the inbred 
strains are still incomplete, which neces-
sitates the use of imperfect imputation 
methods to fi ll the gaps in the analyzed 
data sets.  Second, the information on hap-
lotype block structure continues to 
evolve, and it is not clear how to best 
define the borders between the blocks. 
The genotyping density and the number 
and choice of strains have an eff ect on 
the fi nal haplotype block structure that 
is used for association testing. Th erefore, 
defi ning haplotypes on the basis of SNPs 
spaced at 40-kb intervals might not be 
ideal, but it is unclear to what degree this 
compromises the eff ectiveness of a study 
design. Th ird, an underlying pattern of 
complex relatedness among inbred 
strains may infl ate false-positive rates in 
association studies. This situation is 
analogous to the eff ect of cryptic related-
ness or population structure on the 
results of genome-wide association stud-
ies in human populations. Although effi  -
cient methods for dealing with this 
problem have been developed for human 
studies, diff erent statistical approaches 
are needed for model organisms. 12,13 
Additional problems arise from the fact 
that ACR is a notoriously diffi  cult quan-
titative phenotype to model, mainly 
because of its highly skewed distribution 
in which many individuals have a score 
of zero. Because parametric association 
through a decrease in the number of 
viable glomeruli, leading to a progres-
sive decline of the glomerular fi ltration 
capacity. Th e authors hypothesize that 
susceptibility to age-related kidney dam-
age is, in part, genetically determined. 
Since aging in mice is marked by an 
increase in albuminuria, the authors 
determined urinary albumin-to-creati-
nine ratios (ACRs) in groups of 10 male 
and 10 female mice from 30 inbred 
strains of diff erent ages (12, 18, and 24 
months). In support of the role of genetic 
background, the ACR levels and pro-
gression rates showed striking variation 
across the 30 strains. In addition, the 
level of albuminuria in mice was pro-
foundly aff ected by their sex. Next, the 
authors selected over 60,000 SNPs from 
the available public databases that tag 
the mouse genome at approximately 
40-kb intervals. Th e haplotype blocks 
were inferred by a hidden Markov 
model 10 and tested for association with 
the ACR phenotype. Th e top nine sug-
gestive QTLs were identifi ed, each con-
taining one to seven posit ional 
candidate genes. Tsaih and colleagues 8 
attempted to confi rm these observations 
using human genetic data for loci syn-
tenic to the nine mouse QTLs. Th e gen-
otypes for 820 cases and 885 controls 
from a previously reported genome-
wide association study for diabetic 
nephropathy were used for this pur-
pose. 11 Two signifi cant association sig-
nals were found in these regions: one in 
the non-coding area between the 
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 Figure 1  |  Principles of haplotype association mapping in inbred strains. A limited 
number of ancestral haplotypes (A, B, and C) are subjected to many recombination events as 
generations descend. As a result, the genomic organization of an inbred strain can be viewed as 
a mosaic of ancestral haplotype blocks delineated by historical recombination break points. In 
haplotype association mapping, a pattern of haplotype blocks is inferred from single-nucleotide 
polymorphism  genotypes with the use of computer algorithms. For each of the haplotype blocks, 
the distributions of quantitative phenotypes are compared between the inbred strains grouped by 
a shared haplotype segment. A statistical test is performed for all inferred haplotype blocks across 
the genome. 
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tests rely on the assumption of normal 
distribution,  alternative methods such as 
non-parametric or permutation proce-
dures are needed to derive more accurate 
 P values. Th e trait can also be dichot-
omized on the basis of a predefi ned ACR 
threshold, but this approach generally 
leads to a signifi cant loss of power. Future 
studies that examine kidney pathology 
scores, such as degree of glomeruloscle-
rosis or fi brosis instead of the ACR meas-
urements, may also circumvent this 
problem by providing more powerful 
injury-specifi c phenotypes. Finally, for 
the purpose of testing for signal concord-
ance in humans, a careful selection of 
adequately powered human cohorts with 
disease phenotypes that are closely 
related to those studied in mice is neces-
sary. Because the susceptibilities of mice 
to age-related albuminuria and to dia-
betic nephropathy may have distinctly 
diff erent genetic determination, one can-
not discard the mouse signals that are 
not observed in the human cohort. 
Hopefully, with the increasing number 
of human genome-wide association 
study data sets, more powerful cohorts 
will soon become available to make these 
types of approaches more feasible. Lastly, 
we must remain aware that signifi cant 
associations are not a proof of causality 
but merely represent a screening method 
for identifying genetic variants that war-
rant further research. 
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 In this issue of  Kidney International , 
Szczech and colleagues 1 report on a  post 
hoc analysis of the Correction of Hemo-
globin and Outcomes in Renal Insuffi  -
ciency (CHOIR) study. 2 Th e original 
study was notable for fi nding increased 
risk of a composite cardiovascular end 
point with epoetin-alfa targeted to a 
hemoglobin (Hgb) level of 13.5 as com-
pared with 11.3 g / dl in patients with 
chronic kidney disease (CKD). When 
this is considered together with the 
CREATE (Cardiovascular Risk Reduc-
tion by Early Anemia Treatment with 
Epoetin Beta) study (CKD patients) 3 
and the Normal Hematocrit Cardiac 
Trial (hemodialysis patients), 4 there was 
a strong trend in each study for 
increased risk for mortality with higher 
Hgb targets during erythropoiesis-
 stimulating agent (ESA) treatment. As a 
result, the National Kidney Foundation ’ s 
Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) anemia guidelines 
were revised in 2007 to include an evi-
dence-based warning to avoid Hgb tar-
gets above 13 g / dl in CKD patients 
treated with ESAs. Little, however, has 
been learned about whether higher Hgb 
targets aff ect certain sub-populations 
diff erently. Th e current elegant analysis 
by Szczech  et al. 1 examines the eff ect of 
Hgb target in the CHOIR study on 
two highly relevant sub-populations, 
CKD patients with diabetes mellitus 
and those with congestive heart 
failure (CHF). 
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 Anemia is common in chronic kidney disease (CKD). The CHOIR study 
found increased risk of a composite cardiovascular outcome when 
anemia was treated with epoetin-alfa to a target hemoglobin level of 
13.5 as compared with 11.3 g / dl. Whether this increase applies to all 
patient subgroups equally is unclear. We discuss an analysis by Szczech 
and colleagues of the effects of the higher hemoglobin target in CKD 
patients with diabetes mellitus or congestive heart failure. 
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